Search
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10296ApprovedInvestigational* serotype 6a individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae
Synonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigenTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity.
Dextran
go.drugbank.com/drugs/DB09255ApprovedInvestigationalVet approvedDextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links.
Mixtures: DG Health Sterile Advanced Relief Eye, DG Health Advanced Relief Eye DropsCategories: Compounds used in a research, industrial, or household settingLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalPalifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexTriflupromazine
go.drugbank.com/drugs/DB00508ApprovedVet approvedA phenothiazine used as an antipsychotic agent and as an antiemetic.
Categories: Dopamine D2 Receptor AntagonistsRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalRoflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]